Background: Pulmonary thromboembolism (PTE) is among the leading causes of death following surgery and/or hospital admission. Role of thrombophilic risk factors in the etiology of PTE is well known; But not much data is available on their role in severity of PTE. The aim of this study was to investigate the role of thrombotic risk factors especially PLA2 polymorphism of platelet glycoprotein IIb/IIIa in the severity of PTE. Materials and Methods: Genotyping from Factor-V (FVL) and prothrombin 20210A (PT20210A) mutations were shown to be significant risk factors for PTE and recurrent PTE. The plasma concentrations of platelet glycoprotein IIb/IIIa PLA2 polymorphism, presence of FVL and PT20210A mutations were studied in 37 patients with PTE. Results: Eleven of these patients had recurrent PTE. Lung perfusion scans were scored according to the percentage of vascular obstruction. Patients who had a pulmonary vascular obstruction (PVO) score >50%were compared to those with PVO score<50%. There was no significant difference between patients with PVO score>50% and those with PVO score<50% with regard to the presence of FVL and PT20210A mutations. However, patients with PVO score>50% had a significantly higher frequency of platelet glycoprotein IIb/IIIaPLA2 polymorphism than those with PVO score <50%. Conclusion: Our data suggest that presence of PLA2 is associated with an increased risk of PTE in the Iranian population. The association between recurrent events and coinheritance of more than one thrombophilic genetic risk factor shows that such carriers are at a higher risk of PTE.
INTRODUCTION
Pulmonary thromboembolism is a major health problem worldwide. The annual incidence of PTE in the general population of the Western countries is estimated to be 0.1-0.05% (1, 2) . There are many well-recognized secondary risk factors for PTE. Primary risk factors, also known as congenital thrombophilic risk factors, should be seriously evaluated in patients with a documented, unexplained thrombotic episode. The most commonly reported congenital risk factors are the factor-V 1691G-A (FVL) mutation, prothrombin20210A (PT20210A) mutation, protein-C and -S deficiency and anti-thrombin deficiency (3, 4) .GP IIIa is a highly polymorphic proteinand platelet antigen 1 (PlA1) and 2 (PlA2) are its most common allelic isoforms. In PlA2 allele, cytosine replaces thymidine in exon2, which is phenotypically translated in the substitution of proline for leucine at position 33 of the mature GPIIIa (5) . A previous in vitro study demonstrated 
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Rouhi Boroujeni H, et al. 15 Tanaffos 2014; 13(3): [14] [15] [16] [17] [18] [19] [20] [21] [22] that the PlA2 variant enhanced the binding of GPIIb/IIIa receptor to fibrinogen and consequently increased platelet aggregation induced by agonists (6) . The clinical impact of PlA2 polymorphism has been investigated in several diseases, in which thrombus formation is a key pathogenetic factor. Recently, a high frequency of platelet glycoprotein IIb/IIIa PLA2 polymorphism was shown to be an independent and dose-dependant risk factor for PTE and recurrent PTE (2, 7, 8) . In this study, the authors aimed to investigate the role of some of the congenital thrombophilic risk factors (FVL, PT20210A mutation and high platelet glycoprotein IIb/IIIa PLA2 polymorphism frequency) in severity of PTE.
MATERIALS AND METHODS

Patients and controls
Thirty-seven unrelated patients, 13 males and 24 females, with a mean age of 53.78 years, were recruited from local volunteers with documented PTE and in the first step of research were compared with the control group of 152 unrelated healthy donors (matched by age and sex) with no history of vascular disease were recruited from local volunteers (2). They were recruited from Hajar Hospital, Shahrekord, Iran. Ethics committee of Shahrekord University of Medical Sciences approved this study (2) . Patients provided written informed consent forms. Patients were clinically diagnosed using the Well's criteria and then PTE was confirmed in all patients by high-probability ventilation/perfusion lung scanning performed in Shahrekord Omid Center. In some patients (nearly 60%) spiral CT of the lung and mediastinum with contrast and with PTE protocol was performed in Shahrekord Hajar Hospital to rule out other diseases (2).
Echocardiography was performed for all patients. Eleven of them (34.4%) were identified as having documented recurrent PTE from the hospital records. The inclusion criteria were the incidence of one or more episodes of pulmonary embolism at the time of diagnosis (9) . Twentythree of the patients presented with isolated PTE and nine of which had PTE associated with DVT. Of the 37 patients studied, nine had no specific risk factor for PTE. In the remaining 28 patients, most had more than one risk factor, 15 had immobility, nine had DVT, nine had obesity, one had estrogen compound usage, and two had multiple trauma. None had malignancies or familial history of PTE or DVT. After diagnosis of PTE, blood samples were collected for laboratory studies. Twenty-nine patients received anticoagulation therapy with standard heparin, followed by warfarin. The remaining eight patients had clinically massive PTE and received thrombolytic therapy with streptokinase, followed by the same anticoagulation therapy. Written informed consent was obtained from each patient.
Study design
Perfusion-ventilation lung scans were performed in of patients with doubtful diagnoses.
Sample Collection and DNA Extraction:
Blood samples were collected from all patients at the time of diagnosis. Before the onset of anticoagulation therapy, venous blood was collected in 5 ml Vacutainer tubes with EDTA. DNA was isolated by the phenol chloroform method and quantified using Unico 2100 spectrophotometer. PCR using genomic DNA followed by restriction fragment length polymorphism (RFLP) were done to identify each polymorphism (Thermocycler ASTEC, PC818, Japan). Primers and restriction enzymes were provided by TAG, Copenhagen, Denmark and Fermentas, Russia, and summarized in Table 1 . The thermal cycling conditions are summarized in Table 2 . and sex was calculated using independent sample t-test (2). Regression was used to analyze the relationship between multiple independent polymorphisms and PTE.
Mann-Whitney U test was performed for comparison of the number of mutations in patients with and without recurrent events and family history. All data of genetic factors were calculated in comparison to the control group. 
RESULTS
Clinical characteristics of patients
Patients were recruited for this study from October 2009 to December 2010. (16, 20, 21) . It has been recently suggested that hyperhomocysteinemia may not be a direct cause of thrombosis, but a marker of systemic or endothelial oxidant stress and platelet activation (22) . Our study also demonstrated that the prevalence of FVL was higher in PTE patients than in controls (5.6 versus 2.3%); however, this difference did not reach a significant level. Many studies have indicated the role of FVL mutation in the cause of PTE. A prevalence of 23.5% has been found in patients with pulmonary embolism in Bulgaria (19), significantly higher than controls (23). Coppola et al. (24) and Biswas et al (25) found an association of homozygous FVL and some of the other rare abnormalities with more severe thrombotic phenotypes, but the common polymorphisms, such as heterozygous FVL, were associated with a lower thrombotic risk. Although we found the homozygous to be more prevalent in our patients in contrast to controls (2.8 versus 0.3%), the difference was not significant. The prevalence has been suggested to be significantly higher in thrombotic patients but not in young patients with coronary artery disease in Turkey (16, 26, 27) . The mutation was not found to be in association with PTE in a Chinese/Thai population (19) .
Our data seem to be in agreement with their population rather than whites. This disparity between different cohorts could be related to not only the number of patients but also national risk factors such as higher BMI or smoking that influences the non carriers.
Rouhi Boroujeni H, et al. 19
Tanaffos 2014; 13(3): [14] [15] [16] [17] [18] [19] [20] [21] [22] The prevalence of FIIG20210A mutation was lower in our patients than that previously reported in whites and some other populations (5, 7, 26, 28, 29) , as it was lower in non thrombotic controls as well (30, 31) . Many studies have demonstrated the role of this polymorphism in the pathogenesis of PTE (5, 19) ; however, others found no relationship (19, 32) . Our data are consistent with the latter, as we did not find a significant difference between patients and controls.
The most striking finding was that the PLA2 polymorphism was strongly associated with PTE (P<0.001). The frequency was about three times higher in patients with PTE than in controls (27.8 versus 10.1%), and this polymorphism was the only independent one associated with PTE in a multivariate analysis (P<0.001).
Apparently, this polymorphism increases the affinity of allele in PTE (29) , its role in arterial events has been shown in different studies (2, 34, 35) .
As demonstrated in our study, the coinheritance of more than one investigated genetic polymorphism increased the risk of PTE. Patients with more than one inherited risk factors had also more recurrent events.
Although we did not find a significant difference between the age of patients and controls, the coinheritance of more than one inherited risk factor in patients with recurrent events influenced the age of patients (32 compared (2) found the risk of thrombosis to be higher in the relatives of unprovoked PTE patients with FVL or FII G20210A mutation than in those without such mutations. We did not find a significant difference in the number of mutations in patients with and without the first-degree family history (data not shown). This finding can be related again to the lower prevalence of FVL and FII G20210A polymorphisms in our population.
In this study, PVO score was used to assess the severity of PTE, which was found to be a reliable method of assessing the percentage of PVO (5). It was found that patients with PVO score>50% had significantly higher concentrations of factor VIIIc. It was also shown that patients with high factor-VIIIc concentrations (>150 IU) had an increased risk of experiencing severe PTE (PVOs >50%) (OR: 9.6; 95% CI:1.8-49.4). In the present study, the prevalence of FVL and PT20210A mutations was 14.9% but the prevalence of MTHFR C877T and PLA2 polymorphism was 26%, which are higher than the reported frequencies for healthy Turkish adults (10% and 2.6%, respectively (1).
The data on PTE patients were higher than previous reports (3, 4), but were not associated with the severity of PTE.
To date, there is no consensus about the duration of oral anticoagulant therapy in patients with high factorVIIIc concentrations. The authors believe that because a high factor-VIIIc concentration plays a distinct role in the recurrence of VTE and the severity of PTE, prolonged anticoagulation must be taken into consideration. In patients with PLA2 polymorphism, we recommend anti platelet aggregation therapy after at least six months of anti coagulation therapy (2).
CONCLUSION
Our data suggest that presence of PLA2 is associated with an increased risk of PTE in the Iranian population.
The association between recurrent events and coinheritance of more than one thrombophilic genetic risk factor shows that such carriers are at a higher risk of PTE. 
